Cabozantinib,Nivolumab,Ipilimumab
Exelixis,bms
['ipi/', 'nivo', 'triplet,(-triplete)', '/ipi', 'cabozantinib', 'increase,(-increased)', 'ipilimumab', 'nivolumab']
cabozantinib/ipilimumab/nivolumab triplet hits dfs primary endpoint (vs ipi/nivo). rr 43% +cr 3% are modest. 32% increase in g3/4 toxicity may be explanation. benefit seem in intermediate risk pts. os is going to be important for things to significantly change #esmo22 
Interested in Urology Cancers, biomarkers and drug development.